Cargando…

Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans

To develop novel strategies for prevention and treatment of dyslipidemia, it is essential to understand the pathophysiology of dyslipoproteinemia in humans. Lipoprotein metabolism is a complex system in which abnormal concentrations of various lipoprotein particles can result from alterations in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adiels, Martin, Mardinoglu, Adil, Taskinen, Marja-Riitta, Borén, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653309/ https://www.ncbi.nlm.nih.gov/pubmed/26635628 http://dx.doi.org/10.3389/fphys.2015.00342

Ejemplares similares

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
por: Borén, Jan, et al.
Publicado: (2020)

Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study
por: Björnson, Elias, et al.
Publicado: (2023)

Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects Models
por: Berglund, Martin, et al.
Publicado: (2015)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

Genetic Variation in SULF2 Is Associated with Postprandial Clearance of Triglyceride-Rich Remnant Particles and Triglyceride Levels in Healthy Subjects
por: Matikainen, Niina, et al.
Publicado: (2013)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
por: Dallinga-Thie, Geesje M., et al.
Publicado: (2016)

Personalized Cardiovascular Disease Prediction and Treatment—A Review of Existing Strategies and Novel Systems Medicine Tools
por: Björnson, Elias, et al.
Publicado: (2016)

Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans
por: Borén, Jan, et al.
Publicado: (2020)

Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
por: Zhang, Bai-Hui, et al.
Publicado: (2022)

Dietary Fructose and the Metabolic Syndrome
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
por: Ginsberg, Henry N, et al.
Publicado: (2021)

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
por: Taskinen, Marja-Riitta, et al.
Publicado: (2016)

Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
por: Gugliucci, Alejandro
Publicado: (2023)

A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model
por: Krengel, Annette, et al.
Publicado: (2013)

Cancer Metabolism: A Modeling Perspective
por: Ghaffari, Pouyan, et al.
Publicado: (2015)

Drug Repositioning for Effective Prostate Cancer Treatment
por: Turanli, Beste, et al.
Publicado: (2018)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

A simplified procedure to trace triglyceride‐rich lipoprotein metabolism in vivo
por: Ying, Zhixiong, et al.
Publicado: (2021)

Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride‐rich lipoprotein metabolism
por: Deprince, Audrey, et al.
Publicado: (2023)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Causes and Consequences of Hypertriglyceridemia
por: Packard, Chris J., et al.
Publicado: (2020)

Editorial: The Impact of Systems Medicine on Human Health and Disease
por: Mardinoglu, Adil, et al.
Publicado: (2016)

Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
por: Vallejo-Vaz, Antonio J, et al.
Publicado: (2020)

Identification of Discriminating Metabolic Pathways and Metabolites in Human PBMCs Stimulated by Various Pathogenic Agents
por: Zhang, Xiang, et al.
Publicado: (2018)

Triglyceride-rich lipoproteins prevent septic death in rats
Publicado: (1995)

Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
por: Baratta, Francesco, et al.
Publicado: (2023)

Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease
por: Heo, Ji Hye, et al.
Publicado: (2023)

Meta-Analysis of Adiponectin as a Biomarker for the Detection of Metabolic Syndrome
por: Liu, Zhengtao, et al.
Publicado: (2018)

The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease
por: Zhang, Cheng, et al.
Publicado: (2020)

Personal model‐assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD
por: Mardinoglu, Adil, et al.
Publicado: (2017)

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
por: Toth, Peter P
Publicado: (2016)

Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy
por: Srivastava, Anand, et al.
Publicado: (2016)

Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
por: Reiner, Željko
Publicado: (2018)

Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins
por: Khetarpal, Sumeet A., et al.
Publicado: (2021)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Lipid and Lipoprotein Metabolism in Microglia
por: Loving, Bailey A., et al.
Publicado: (2020)

Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study
por: Matikainen, Niina, et al.
Publicado: (2018)

Understanding the Representative Gut Microbiota Dysbiosis in Metformin-Treated Type 2 Diabetes Patients Using Genome-Scale Metabolic Modeling
por: Rosario, Dorines, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nvu8fm25ogo6s4o7cmb5rth232